title: Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model.
abstract: OBJECTIVE
  The aim of the study was to assess the effect of paricalcitol on the experimental contrast-induced nephropathy (CIN) model. We hypothesised that paricalcitol may prevent CIN.
  
  
  METHODS
  32 Wistar albino rats were divided into four groups (n=8 each): control group, paricalcitol group, CIN group and paricalcitol plus CIN group. Paricalcitol (0.4 µg kg(-1) day(-1)) was given intraperitoneally for 5 consecutive days prior to induction of CIN. CIN was induced at day 4 by intravenous injection of indometacin (10 mg kg(-1)), Nω-nitro-L-arginine methyl ester (L-NAME, 10 mg kg(-1)) and meglumine amidotrizoate (6 ml kg(-1)). Renal function parameters, oxidative stress biomarkers, histopathological findings and vascular endothelial growth factor (VEGF) immunoexpression were evaluated.
  
  
  RESULTS
  The paricalcitol plus CIN group had lower mean serum creatinine levels (p=0.034) as well as higher creatinine clearance (p=0.042) than the CIN group. Serum malondialdehyde and kidney thiobarbituric acid-reacting substances levels were significantly lower in the paricalcitol plus CIN group than in the CIN group (p=0.024 and p=0.042, respectively). The mean scores of tubular necrosis (p=0.024), proteinaceous casts (p=0.038), medullary congestion (p=0.035) and VEGF immunoexpression (p=0.018) in the paricalcitol plus CIN group were also significantly lower.
  
  
  CONCLUSIONS
  This study demonstrates the protective effect of paricalcitol in the prevention of CIN in an experimental model.
authors: Department of Nephrology, Van Yuksek Ihtisas Hospital, Van, Turkey. elifaribakir@gmail.com
authors: E
authors: E
authors: Ari
authors: A E
authors: AE
authors: Kedrah
authors: Y
authors: Y
authors: Alahdab
authors: G
authors: G
authors: Bulut
authors: Z
authors: Z
authors: Eren
authors: O
authors: O
authors: Baytekin
authors: D
authors: D
authors: Odabasi
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D015415:Biomarkers / Q000378:metabolism; D003287:Contrast Media / Q000633:toxicity*; D004872:Ergocalciferols / Q000494:pharmacology*; D007150:Immunohistochemistry; D007674:Kidney Diseases / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D008297:Male; D018384:Oxidative Stress / Q000502:physiology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D012076:Renal Agents / Q000494:pharmacology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D003287:Contrast Media; D004872:Ergocalciferols; D012076:Renal Agents; D042461:Vascular Endothelial Growth Factor A; C084656:paricalcitol